Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3857210 · 4 trials · 4 indications
The NRS was used to describe pain severity. Participants were asked to describe their average pain over the past 24 hours, on a scale of 0 to 10: 0 = no pain, and 10 = pain as bad as you can imagine. Posterior mean change from baseline, 95 percent (%) credible interval was derived using Bayesian mixed model repeated measures. The data presented are the posterior mean with a 95% credible interval.
The NRS was used to describe pain severity. Participants were asked to describe their average pain over the past 24 hours, on a scale of 0 to 10: 0=no pain, and 10=pain as bad as you can imagine. Posterior mean change from baseline, 95 percent (%) credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval.
Change from baseline in brain RO of LY3857210 measured by \[18F\]-LY3818850 PET scan
| Arm | Type | Description |
|---|---|---|
| LY3857210 | EXPERIMENTAL | Participants received 45 milligrams (mg) of LY3857210 orally once daily for up to 8 weeks. |
| Placebo | PLACEBO_COMPARATOR | Participants received placebo orally once daily for up to 8 weeks. |
| 45 mg LY3857210 | EXPERIMENTAL | Participants received 45 milligram (mg) LY3857210 orally once daily for up to 8 weeks. |
| Name | Type | Description |
|---|---|---|
| LY3857210 | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
Inclusion Criteria: * Have a visual analog scale (VAS) pain value ≥40 and \<95 during screening. * Have a history of daily pain for at least 12 weeks based on participant report or medical history. * Have a body mass index \<40 kilograms per meter squared (kg/m²) (inclusive). * Are willing to maint...
Top 20 of 25 competitors
LY3857210 is an investigational small molecule being studied for the treatment of pain conditions, including osteoarthritis, diabetic peripheral neuropathic pain, and chronic low-back pain. It has also been evaluated in healthy participants. The drug is being developed by Eli Lilly and Company and is currently in Phase 2 clinical development.
LY3857210 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker LLY. The drug is an investigational small molecule in Phase 2 clinical development for pain indications.
LY3857210 is in Phase 2 clinical development. It has completed Phase 1 and Phase 2 trials, including studies in healthy participants and in patients with osteoarthritis, diabetic peripheral neuropathic pain, and chronic low-back pain. The drug is not yet approved and remains investigational.
LY3857210 has been studied in several clinical trials, including NCT05292040 in healthy participants, NCT05620563 in osteoarthritis pain, NCT05620576 in diabetic peripheral neuropathic pain, and NCT05630196 in chronic low-back pain. All of these trials have been completed.
LY3857210 is the primary name for this investigational drug. No alternative names have been reported for this compound in the clinical trial records. It is identified solely by the code LY3857210 in the studies conducted by Eli Lilly and Company.